Mark Kong CFA

Stock Analyst at DBS

(1.74)
# 3,410
Out of 5,014 analysts
30
Total ratings
52.6%
Success rate
0.3%
Average return

Stocks Rated by Mark Kong CFA

BeOne Medicines AG
Sep 28, 2026
Reiterated: Buy
Price Target: $290.00
Current: $225.40
Upside: +28.66%
Consun Pharmaceutical Group Limited
Sep 17, 2026
Reiterated: Buy
Price Target: $26.00
Current: $14.84
Upside: +75.20%
Innovent Biologics, Inc.
Sep 15, 2026
Reiterated: Buy
Price Target: $144.00
Current: $98.05
Upside: +46.86%
CSPC Pharmaceutical Group Limited
Sep 10, 2026
Initiated Coverage: Buy
Price Target: $13.70
Current: $10.07
Upside: +36.05%
Sino Biopharmaceutical Limited
May 20, 2026
Initiated Coverage: Buy
Price Target: $6.50
Current: $5.71
Upside: +13.84%
Laekna, Inc.
Mar 20, 2026
Reiterated: Buy
Price Target: $24.16
Current: $8.27
Upside: +192.32%
Sinopharm Group Co. Ltd.
Dec 12, 2024
Upgraded: Buy
Price Target: $25.00
Current: $14.86
Upside: n/a
China Resources Medical Holdings Company Limited
Oct 24, 2024
Reiterated: Buy
Price Target: $7.50
Current: $2.41
Upside: n/a
Sanofi
Oct 11, 2024
Reiterated: Buy
Price Target: n/a
Current: $41.23
Upside: n/a
Vertex Pharmaceuticals
Oct 8, 2024
Reiterated: Hold
Price Target: n/a
Current: $522.81
Upside: n/a
Reiterated: Hold
Price Target: n/a
Current: $261.59
Upside: n/a
Reiterated: Buy
Price Target: n/a
Current: $192.57
Upside: n/a